Nico Gagelmann

Nico Gagelmann Shares Article on How Remission Conversion Drives Outcomes After CAR T-cell Therapy for Multiple Myeloma

Nico Gagelmann, Young National Society Ambassador at European Hematology Association (EHA) and Chair of the CAR-T for plasma cell disorder committee at The EBMT, shared a post on X:

“Finally out
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma
Now in Blood Journals Portfolio
Timely for EHA2025″

Title: Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

Authors: Maximilian Merz, Nico Gagelmann, Samih Smaili, Sarah Flossdorf, Sandra Sauer, Christof Scheid, Bastian von Tresckow, Gerald Georg Wulf, Katja C Weisel, Igor Blau, Monika Engelhardt, Ralph Wäsch, Natalie Schub, Raphael Teipel, Judith S. Hecker, Johannes M. Waldschmidt, Britta Besemer, Ben-Niklas Baermann, Simon Call, Leo Hansmann, Francis Ayuketang Ayuk, Marc S. Raab, Hermann Einsele, Uwe Platzbecker, Nicolaus Kröger

You can read the Full Article on Blood Journals Portfolio

Nico Gagelmann Shares Article on How Remission Conversion Drives Outcomes After CAR T-cell Therapy for Multiple Myeloma

More posts featuring Nico Gagelmann.

Bastian von Tresckow Ben-Niklas Baermann Britta Besemer cancer CAR T-cell therapy Christof Scheid Francis Ayuketang Ayuk Gerald Georg Wulf Hermann Einsele Igor Blau Johannes M Waldschmidt Judith S. Hecker Katja C. Weisel Leo Hansmann Marc S. Raab Maximilian Merz Monika Engelhardt multiple myeloma Natalie Schub Nico Gagelmann Nicolaus Kröger OncoDaily Oncology Ralph Wäsch Raphael Teipel Remission Conversion Samih Smaili Sandra Sauer Sarah Flossdorf Simon Call Uwe Platzbecker